Mucin-Based Biotherapies for Pseudomonas aeruginosa Lung Infection
Abstract
The purpose of this project is to demonstrate that MUC1 synthetic peptides will protect against Pseudomonas aeruginosa lung infection using both in vitro and in vivo model systems. For months 1-12 of the project, studies were conducted demonstrating that MUC1 20-,40-, 60-, 80-, and 100-mer peptides 1) bound to P. aeruginosa bacteria and its flagella, 2) competitively inhibited P. aeruginosa and its flagella binding to human lung cells, and flagella-dependent bacterial motility 3) were not cytotoxic to lung cells, 4) did not affect lung cell barrier formation, 5) exhibited no damage to mouse lung, liver or kidney when administered in vivo, and 6) displayed appropriate lung bioavailability in vivo. P. aeruginosa laboratory and clinical strains were tested. In all of the assays performed, the MUC1 peptides exhibited a relative potency according to the rank order 100-mer > 80-mer > 60-mer > 40-mer > 20-mer. These studies, and those to be performed in months 13-18 of the project, will provide preclinical data for future human clinical trials.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2020
- Accession Number
- AD1098907
Entities
People
- Erik P. Lillehoj
Organizations
- University of Maryland, Baltimore